

## 2022 ICD-10-CM Casefinding List: Short Version (Required) EFFECTIVE DATES: 10/1/2021-9/30/2022

2022 COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors		
ICD-10 Code	Explanation of Code	
C00 C43, C4A, C45 C48, C49 -C96	Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies	
C44.00, C44.09	Unspecified/other malignant neoplasm of skin of lip	
C44.10-, C44.19-	Unspecified/other malignant neoplasm of skin of eyelid	
C44.13-	Sebaceous cell carcinoma of skin of eyelid, including canthus Note: Effective 10/1/2018	
C44.20-, C44.29-	Unspecified/other malignant neoplasm skin of ear and external auricular canal	
C44.30-, C44.39-	Unspecified/other malignant neoplasm of skin of other/unspecified parts of face	
C44.40, C44.49	Unspecified/other malignant neoplasm of skin of scalp & neck	
C44.50-, C44.59-	Unspecified/other malignant neoplasm of skin of trunk	
C44.60-, C44.69- C44.70-, C44.79-	Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder	
C44.70-, C44.79-	Unspecified/other malignant neoplasm of skin of lower limb, including hip Unspecified/other malignant neoplasm of skin of overlapping sites of skin	
C44.90, C44.99	Unspecified/other malignant neoplasm of skin of unspecified sites of skin	
C49.A-	Gastrointestinal Stromal Tumors Note: All GIST tumors are now reportable starting in 2021 (per ICD-O-3.2), including GIST, NOS	
D00 D05, D07 D09	In-situ neoplasms Note 1: Excludes carcinoma in situ tumors of the cervix (D06) Note 2: Excludes prostatic intraepithelial neoplasia (PIN III) (8148/2) of the prostate. Other prostate in situ histologies are reportable Note 3: For D04 (carcinoma in situ of skin), excludes basal and squamous cell in situ lesions	
D13.7	Benign neoplasm of endocrine pancreas Note: Effective 1/1/2021:	
	Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2 • Islet cell adenoma • Nesidioblastoma • Islet cell adenomatosis • Insulinoma • Beta cell adenoma	
D18.02	Hemangioma of intracranial structures and any site	
D21.4, D48.1	Benign neoplasm of connective and other soft tissue of abdomen Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O- 3.2 • Gastrointestinal stromal tumor, NOS/GIST, NOS/Gastrointestinal autonomic nerve tumor/GANT/Gastrointestinal pacemaker cell tumor (8936/1, now 8936/3)	
Page   1	12/17/202	



2022 COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors		
ICD-10 Code	Explanation of Code	
D23.9	Other benign neoplasm of skin Benign carcinoid tumors of other sites Note: Effective 1/1/2021: Review these codes to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O- 3.2 • Aggressive digital papillary adenoma (c44_) (8408/1, but now 8408/3)	
D3A	Benign carcinoid tumors of other sites Note: Effective 1/1/2021: Review these codes to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O-3.2 • Carcinoid tumor, argentaffinoma, NOS (8240/1, now 8241/3) • Enterochromaffin-like cell carcinoid, NOS (8242/1, now 8241/3)	
D32	Benign neoplasm of meninges (cerebral, spinal and unspecified)	
D33	Benign neoplasm of brain and other parts of central nervous system	
D35.00 - D35.02	<ul> <li>Benign neoplasm of adrenal gland Note: Effective 1/1/2021: Review this code to look for the following which was previously a benign (8700/0) tumor of the adrenal gland, but is now malignant per ICD-O-3.2 (8700/3)</li> <li>Pheochromocytoma</li> <li>Adrenal medullary paraganglioma</li> <li>Chromaffin paraganglioma</li> <li>Chromaffin tumor</li> <li>Chromaffinoma</li> </ul>	
D35.2 - D35.4	Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland	
D37.8	<ul> <li>Neoplasm of uncertain behavior of other specified digestive organs (includes uncertain behavior of pancreas) Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</li> <li>Pancreatic endocrine tumor, NOS (C259, 8150/1, now 8150/3)</li> <li>Islet cell tumor, NOS (C259, 8150/1, now 8150/3)</li> <li>Glucagonoma, NOS (C259, 8152/1, now 8152/3)</li> <li>Alpha cell tumor, NOS (C259, 8152/1, now 8152/3)</li> <li>Glucagon-like peptid-producing tumor (C259, 8152/1, now 8152/3)</li> <li>Somastostatinoma, NOS (8156/1, now 8156/3)</li> <li>Somatostatin cell tumor, NOS (8156/1, now 8156/3)</li> <li>Endocrine tumor, functioning, NOS (8158/1, now 8158/3)</li> <li>ACTH-producing tumor (8158/1, now 8158/3)</li> </ul>	
D42, D43	Neoplasm of uncertain or unknown behavior of meninges, brain, CNS	
D44.3 - D44.5	Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland	
D44.6	Neoplasm of uncertain behavior of carotid body Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2 • Carotid body tumor/Carotid body paraganglioma (8692/1, now 8692/3)	
D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O- 3.2 • Paraganglioma, NOS (8680/1, now 8680/3) • Sympathetic paraganglioma (8681/1, now 8681/3) • Parasympathetic paraganglioma (8682/1, now 8682/3) • Glomulus jugulare tumor, NOS/jugular paraganglioma/juglotympanic paraganglioma (8690/1, now 8690/3) • Aortic body tumor/aortic body paraganglioma/aorticopulmonary paraganglioma (8691/1, now 8691/3) • Extra-adrenal paraganglioma, NOS/nonchromaffin paraganglioma, NOS/chemodectoma (8693/1, now 8693/3)	



2022 COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors		
ICD-10 Code	Explanation of Code	
D45	Polycythemia vera (9950/3) ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1)	
D46	Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9993)	
D47.02	Systemic mastocytosis	
D47.1	Chronic myeloproliferative disease (9963/3, 9975/3) ICD-10-CM Coding instruction note: Excludes the following: Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_) Chronic myeloid leukemia BCR/ABL-positive (C92.1_) Myelofibrosis & Secondary myelofibrosis (D75.81) Myelophthisic anemia & Myelophthisis (D61.82)	
D47.3	Essential (hemorrhagic) thrombocythemia (9962/3) Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia	
D47.4	Osteomyelofibrosis (9961/3) Includes: Chronic idiopathic myelofibrosis Myelofibrosis (idiopathic) (with myeloid metaplasia) Myelosclerosis (megakaryocytic) with myeloid metaplasia) Secondary	
D47.9	myelofibrosis in myeloproliferative disease Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3)	
D47.Z-	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3)	
D48.0	Note: Effective 1/1/2021, PTLD (9971/3) is no longer reportable (9971/1) Neoplasm of uncertain behavior of bone and articular cartilage Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O- 3.2 • Clear cell odontogenic tumor (9341/1, now 9341/3)	
D49.2	Neoplasm of unspecified behavior of digestive organs (includes unspecified behavior of pancreas) Note: Review this code to look for the following which were previously unknown behavior tumors of the pancreas, but are now malignant tumors per ICD-O-3.2 (Histology 8150/3) • Pancreatic endocrine tumor, NOS • Islet cell tumor, NOS	
D49.6, D49.7	Neoplasm of unspecified behavior of brain, endocrine glands and other CNS	
D72.110	Idiopathic hypereosinophilic syndrome [HES] (9964/3) Effective 10/1/2020 Note: Previous code (FY 2015- FY 2020): D72 1: Fosinophilia	
D72.111	Note: Previous code (FY 2015- FY 2020): D72.1: Eosinophilia Lymphocytic Variant Hypereosinophilic Syndrome [LHES] (9964/3) Effective 10/1/2020 Note: Previous code (FY 2015- FY 2020): D72.1: Eosinophilia Syndrome [LHES]	
D72.118	D72.118 Other hypereosinophilic syndrome (9964/3) Effective 10/1/2020 Note: Previous code (FY 2015- FY 2020): D72.1: Eosinophilia	
D72.119	Hypereosinophilic syndrome [HES], (9964/3) Effective 10/1/2020 Note: Previous code (FY 2015- FY 2020): D72.1: Eosinophilia	
R85.614	Cytologic evidence of malignancy on smear of anus	



2022 COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors		
ICD-10 Code	Explanation of Code	
R87.614	Cytologic evidence of malignancy on smear of cervix	
R87.624	Cytologic evidence of malignancy on smear of vagina	

1 Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).

*NOTE:* Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases

Note: VIN 3, VAIN 3, AIN 2-3, AIN 3 (squamous intraepithelial neoplasia Grade 3) and juvenile astrocytoma, pilocytic astrocytoma, and piloid astrocytoma **ARE** reportable to the Oregon State Cancer Registry.

**Exclusions**: Basal/squamous cell carcinoma of skin. **However, if skin of genitalia then it is reportable to OSCaR.** 

\* in situ carcinoma of cervix uteri and PIN III are not reportable.

## \*\* Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List.

Reference: Surveillance Epidemiology and End Results (SEER) Program. Comprehensive ICD-10-CM Casefinding list for reportable tumor.



## 2022 ICD-10-CM Casefinding List: Supplemental

Effective for cases diagnosed 10/1/2021-9/30/2022

NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases

*NOTE:* For the 2022 ICD-10-CM Supplemental Casefinding List please visit the SEER website: <u>https://seer.cancer.gov/tools/casefinding/icd-10-cm-casefinding-list.20220105.pdf</u>